NCT06944496View on ClinicalTrials.gov

A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

616

Participants

Timeline

Start Date

May 15, 2025

Primary Completion Date

May 15, 2028

Study Completion Date

May 15, 2030

Conditions
Gastric Carcinoma
Interventions
BIOLOGICAL

Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine

Disitamab Vedotin: 2.5 mg/kg, IV, D1, Q2W; Tislelizumab: 200 mg, IV, D1, Q3W Oxaliplatin: 100 mg/m², IV, D1, Q3W; Capecitabine: 750 mg/m², po, BID, D1-D14, Q3W

BIOLOGICAL

Tislelizumab+Oxaliplatin+Capecitabine

Tislelizumab: 200 mg, IV, D1, Q3W Oxaliplatin: 130 mg/m², IV, D1, Q3W; Capecitabine: 1000 mg/m², po, BID, D1-D14, Q3W

Trial Locations (1)

100021

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

RemeGen Co., Ltd.

INDUSTRY

NCT06944496 - A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Biotech Hunter | Biotech Hunter